United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 100 mg - progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. they are also indicated for use in secondary amenorrhea. progesterone capsules should not be used in women with any of the following conditions: 1. progesterone capsules should not be used in patients with known hypersensitivity to its ingredients. progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts. 2. undiagnosed abnormal genital bleeding. 3. known, suspected, or history of breast cancer. 4. active deep vein thrombosis, pulmonary embolism or history of these conditions. 5. active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. 6. known liver dysfunction or disease. 7. known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

avkare, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 100 mg - progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. they are also indicated for use in secondary amenorrhea. progesterone capsules should not be used in women with any of the following conditions: - progesterone capsules should not be used in patients with known hypersensitivity to itsingredients. progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts. - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. - known liver dysfunction or disease. - known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 100 mg - progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. they are also indicated for use in secondary amenorrhea. progesterone capsules should not be used in women with any of the following conditions: - progesterone capsules should not be used in patients with known hypersensitivity to itsingredients. progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts. - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. - known liver dysfunction or disease. - known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 10 mg - medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. mpa tablets is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions. - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to mpa. - known liver impairment or disease. - known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 5 mg - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions:

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension, usp is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension, usp long-term [see warnings and precautions (5.1) ]. the use of medroxyprogesterone acetate injectable suspension, usp is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension, usp (medroxyprogesterone acetate) or any of its other ingredie

United States - English - NLM (National Library of Medicine)

american regent, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 50 mg in 1 ml - this drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. - current or past history of thrombophlebitis, thromboembolic disorders, or cerebral apoplexy. - liver dysfunction or disease. - known or suspected malignancy of breast or genital organs. - undiagnosed vaginal bleeding. - missed abortion. - known sensitivity to progesterone injection, usp.

United States - English - NLM (National Library of Medicine)

greenstone llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate (mpa) injectable suspension, usp is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of mpa injectable suspension, usp is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of mpa injectable suspension, usp is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to mpa injectable suspension, usp (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)]

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension, usp is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension, usp long-term (see warnings.) it is a long-term injectable contraceptive in women when administered at 3-month (13-week) intervals. dosage does not need to be adjusted for body weight. in five clinical studies using medroxyprogesterone acetate injectable suspension, usp, the 12-month failure rate for the group of women treated with medroxyprogesterone acetate injectable suspension, usp was zero (no pregnancies reported) to 0.7 by life-table method. pregnancy rates with contraceptive measures are typically reported for only the first year of use as shown in table 1. except for intrauterine devices (iud)

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate (mpa) injectable suspension, usp is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use mpa injectable suspension, usp long-term [see warnings and precautions (5.1)] . the use of mpa injectable suspension, usp is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to mpa injecta